Skip to main content

Does Caplyta cause weight gain?

Medically reviewed by Philip Thornton, DipPharm. Last updated on Oct 1, 2024.

Official answer

by Drugs.com

Caplyta (lumateperone) treatment is not associated with the weight gain that some other antipsychotic drugs are. Caplyta is an atypical antipsychotic that is used to treat schizophrenia and bipolar depression in adults.

Results from a number of trials combined together showed that the weight gain observed in patients treated with Caplyta was similar to the weight gain observed in patients who received placebo.

Positive results were also reported by a study that followed patients for one year after they switched from standard of care to Caplyta. Significant improvements in mean body weight were observed during the year of treatment (-2.1 kg, P <0.001) when mean body weights from the beginning and end of the year were compared. Significant reductions in body mass index (BMI) and waist circumference were also observed.

References

Read next

What is the mechanism of action for Caplyta?

Caplyta (lumateperone) is thought to work by changing the activity of certain chemicals called neurotransmitters in the brain. These neurotransmitters include dopamine, glutamate, and serotonin. Continue reading

Caplyta savings card: Do I qualify and how much can I save?

To be eligible for the Caplyta Savings Card, you must be 18 years of age or older, have a prescription for Caplyta, and have private commercial insurance. It cannot be used with federal or state health programs. If you qualify, you may pay as little as $0 for the first two fills of a 30-day supply of Caplyta, up to the maximum lifetime benefit which is based on the current list price of a 30-day supply. After that, you pay $15 for fills up to a 90-day supply (maximum benefit $600). Continue reading

How long does it take Caplyta to work?

Patient with schizophrenia started to show improved Positive and Negative Syndrome Scale (PANSS) total scores after one week of treatment with Caplyta (lumateperone), according to the results of a phase III trial. PANSS is a scale used to measure the severity of schizophrenia symptoms. Symptoms continue to improve the longer you take the drug. Continue reading

Related medical questions

Drug information

Related support groups